In the case of patients belonging to the Luminal A, Luminal B, and HER2+ subtypes, we recorded a p53 mutant status in 13 cases, and a p53 wildtype status in 17 cases without a statistically significant impact on the tumor response rate to NAC (p = 0.325). Here, ERBB2 is linked to neoplasm.